Eli Lilly wins preliminary injunction in Mounjaro case in drugmakers' ongoing battle with compounding pharmacies, wellness spas
A federal judge has temporarily blocked a Minnesota medical spa from using Eli Lilly’s Mounjaro trademark to advertise compounded drugs that contain tirzepatide.
Eli Lilly and its GLP-1 rival Novo Nordisk have been on a legal campaign to stop wellness centers and compounding pharmacies that they believe are improperly advertising the products. The preliminary injunction marks an early win for Lilly, whose fast-selling type 2 diabetes drug, also known as tirzepatide, was also recently approved under the brand name Zepbound for weight management.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.